Screening Screening tests are used to determine the test to detect hepatitis B surface status of a disease, disorder or other antigen in donated blood physiological state in an asymptomatic prenatal rubella IgG screening in individual. pregnant women These types of tests include genetic prenatal genetic testing for screening assays, tests for physiological syndrome) trisomy 21 (Down’s typing, and tests used to reduce the risk of newborn genetic testing for infectious disease transmission, such as phenylketonuria assays for prenatal screening and donor tests for the determination of screening (transfusion or transplantation). HLA, blood groups and blood group factors for donor Depending on the nature of the condition matching and the targeted patient population, screening tests may be used routinely or may be restricted to patients. ‘at risk’ These tests are designed to evaluate an current state. individual’s Monitoring Monitoring tests are used for the intraoperative iPTH monitoring measurement of analyte levels for the during parathyroidectomy purpose of adjusting surgery to confirm removal of treatments/interventions as required. abnormal tissue Monitoring tests include the following: self-test glucose monitoring to allow for quick responses to Assays which are used to ensure that an hyperglycemia or hypoglycemia analyte remains within physiological therapeutic drug monitoring of levels or within an established immunosuppressants to prevent therapeutic drug range. These types of rejection of transplanted organs monitoring tests are designed to viral load testing of patients evaluate an current state. individual’s known to be infected with HIV to determine treatment response Assays which are used for serial and adjust therapy if necessary measurement, whereby multiple determinations are taken over time. monitoring of CA 15-3 levels in These types of monitoring tests are breast cancer patients in typically used for the remission to detect recurrence detection/assessment of disease test for the detection of progression/regression, disease transcripts to monitor recurrence, minimum residual disease, response/resistance in patients response/resistance to therapy, and/or undergoing treatment for acute adverse effects due to therapy. These lymphoblastic leukemia (ALL) or types of monitoring tests are designed to chronic myeloid leukemia (CML) evaluate changes in an state individual’s test for immunoglobulin and receptor gene rearrangements for the detection of minimal residual disease in cancer patients.
Screening Screening tests are used to determine the status of a disease, disorder or other physiological state in an asymptomatic individual. These types of tests include genetic screening assays, tests for physiological typing, and tests used to reduce the risk of infectious disease transmission, such as assays for prenatal screening and donor screening (transfusion or transplantation). Depending on the nature of the condition and the targeted patient population, screening tests may be used routinely or may be restricted to ‘at risk’ patients. These tests are designed to evaluate an individual’s current state. test to detect hepatitis B surface antigen in donated blood prenatal rubella IgG screening in pregnant women prenatal genetic testing for trisomy 21 (Down’s syndrome) newborn genetic testing for phenylketonuria tests for the determination of HLA, blood groups and blood group factors for donor matching Monitoring Monitoring tests are used for the measurement of analyte levels for the purpose of adjusting treatments/interventions as required. Monitoring tests include the following: Assays which are used to ensure that an analyte remains within physiological levels or within an established therapeutic drug range. These types of monitoring tests are designed to evaluate an individual’s current state. Assays which are used for serial measurement, whereby multiple determinations are taken over time. These types of monitoring tests are typically used for the detection/assessment of disease progression/regression, disease recurrence, minimum residual disease, response/resistance to therapy, and/or adverse effects due to therapy. These types of monitoring tests are designed to evaluate changes in an individual’s state intraoperative iPTH monitoring during parathyroidectomy surgery to confirm removal of abnormal tissue self-test glucose monitoring to allow for quick responses to hyperglycemia or hypoglycemia therapeutic drug monitoring of immunosuppressants to prevent rejection of transplanted organs viral load testing of patients known to be infected with HIV to determine treatment response and adjust therapy if necessary monitoring of CA 15-3 levels in breast cancer patients in remission to detect recurrence test for the detection of transcripts to monitor response/resistance in patients undergoing treatment for acute lymphoblastic leukemia (ALL) or chronic myeloid leukemia (CML) test for immunoglobulin and receptor gene rearrangements for the detection of minimal residual disease in cancer patients.